Pule'an combined with solifenacin in treatment of overactive bladder patients with benign prostatic hyperplasia after resection
Objective To investigate the efficacy of Pule'an combined with solifenacin succinate in treatment of overactive bladder(OAB)patients with benign prostatic hyperplasia(BPH)after resection.Methods Sixty patients with OAB after holmium laser enucleation of the prostate who were admitted in Lishui Municipal People's Hospital from May 2022 to June 2023 were enrolled in the study,including 31 cases treated with Pule'an and solifenacin succinate(combination group),and 29 cases treated with solifenacin succinate alone(monotherapy group).The overactive bladder symptom score(OABSS),OAB remission rate(OABSS decreased by less than 3 points and did not increase significantly within 1 day),residual urine volume,quality of life score(QOL)and international prostate symptom score(IPSS)were compared between the two groups after treatment.Univariate and multivariate Cox analyses were used to identify factors influencing OAB remission.Results The OABSS score in combination group was lower and OAB remission rate in combination group was higher than those in monotherapy group 0.5,1 month after surgery(all P＜0.05).There were no significant differences in OABSS,residual urine volume,QOL,IPSS,and OAB remission rate between the two groups at 3 months after resection(all P＞0.05).Combination therapy(HR=0.562)was an independent protective factor for OAB,while OABSS score of 4-5(HR=2.082),preoperative QOL score of 4-6(HR=2.180),and smoking(HR=3.466)were independent risk factors for OAB(all P＜0.05).Conclusion Combination therapy with Pule'an and solifenacin succinate significantly alleviates OAB symptoms and serves as an independent enhancing factor for OAB remission.
万方数据
维普
